Replies to post #216413 on Biotech Values

[DewDiligence]

RVNC—Advancement to a 2b is the absolute wrong goal for shareholders in the long run. A successful outcome of a well designed trial is my preferred goal.

That’s a different way of expressing the same goal. I.e., I’m making the assumption that RVNC will advance the PF program to phase-2b only if the second phase-2a trial produces data that warrant advancing the program.